Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
2,931
Views
3
CrossRef citations to date
0
Altmetric
Report

Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction

Fabian BickelAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
François GriaudAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Wolfram KernAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Frieder KroenerAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Manuela GritschAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Jérôme DayerAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Samuel BarteauAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Blandine DenefeldAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Chi-Ya Kao-ScharfAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Manuel LangAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Izabela Slupska-MuanzaAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Carla SchmidtAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Matthias BergAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Jürgen SiggAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Lina BoadoAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandView further author information
&
Dirk CheliusAnalytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, SwitzerlandCorrespondence[email protected]
View further author information
 show all
Article: 2151075 | Received 06 Jul 2022, Accepted 18 Nov 2022, Published online: 15 Dec 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.